Vicebio develops vaccines targeting life-threatening respiratory viral infectious diseases using its patented Molecular Clamp technology, which stabilizes viral glycoproteins to deliver highly protective, ready-to-use, fully liquid vaccines.  The technology was invented at The University of Queensland, Australia, and exclusively licensed to Vicebio by UniQuest.

Vicebio

Colin Walsh

Mark Chin

Cariad Chester

Emmanuel Hanon

Koen Huygens

Giovanni Della Cioppa

Jean Smal

England Startups Founded in 2019

Companies With Fewer Than 10 Employees (Top 10K)

Europe, Middle East, and Africa (EMEA) Companies (Top 10K)

Biotechnology Companies (Top 10K)

Vicebio is committed to employing the Molecular Clamp Technology to create vaccines against next-generation respiratory viruses.  Vicebio is a biopharmaceutical business that creates innovative vaccinations to prevent potentially fatal respiratory viral infections.

TCG Crossover

Series B - Vicebio

London

England

United Kingdom

Europe

Fierce Biotech Fundraising Tracker ’24: Genespire gathers $52M series B; Vicebio secures $100M

European VC Funding Drops To Lowest Quarter In 4 Years, Despite Uptick For German Startups

Vicebio Raises $100M in Series B Financing

Vicebio hauls in $100M series B to push RSV combo vaccine through phase 1

UK vaccine startup Vicebio snags $100M to take on GSK, Pfizer and Moderna

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 6, 2024 11:28 PM	1e91c8db
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 6, 2024 11:28 PM	eff134d8
crunchbase trigger	general	Nov 6, 2024 11:28 PM	85cf13ce
crunchbase profile	general	Nov 7, 2024 10:27 PM	c3732ba8
li profile	general	Nov 6, 2024 11:28 PM	3c7e5352
translate crunchbase fundingrounds	general	Nov 7, 2024 11:03 PM	51edcccb
peers	general	Nov 6, 2024 11:28 PM	e7af50ab
news basic	general	Nov 6, 2024 11:28 PM	de148282
bundesanzeiger	filings
financials download nd	financials
private financials	financials

VICE

COM:VICEBIO

Vicebio